Market news

Detailed price information for Mangoceuticals Inc (MGRX-Q) from The Globe and Mail including charting and trades.

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies. DALLAS, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today

MOU will assess the technical feasibility of integrating Nuclea’s modular reactor technology into New Mining’s data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Dallas, Texas, Aug. ...

Mangoceuticals Shares surged 49.24% after hours as Nuclea Energy advanced nuclear reactor plans boosted merger-related optimism.

Detailed price information for Mangoceuticals Inc (MGRX-Q) from The Globe and Mail including charting and trades.

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor toward demonstration and deployment Dallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner’s wholly owned subsidiary, Nuclea Energy USA Inc. (“Nuclea USA”), has signed a memorandu

Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1, 2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US $1.00 per shar

Mangoceuticals (MGRX) said Thursday it has struck a definitive business combination agreement with N

Business Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that it has entered into a definitive business combination agreement (the “Agreement”) with Nuclea Energy Inc. (“Nuclea”), an advanced nuclear technology company founded in August 2023 and headquartered in M

Transaction positions Nuclea to fund the development and commercialization of its lead-cooled, factory-built microreactor as AI and data center growth drives a generational expansion in U.S. electricity demandMississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announced...

Mangoceuticals shares jumped 137.77% after hours following its definitive business combination agreement with Nuclea Energy.